循环HOXA9甲基化肿瘤DNA:BRCA突变上皮性卵巢癌PARP抑制剂疗效的新型生物标志物
该研究基于一项veliparib治疗铂耐药BRCA突变卵巢癌的II期试验(n=32),采用微滴数字PCR纵向检测血浆HOXA9启动子甲基化循环肿瘤DNA。治疗3周期后可检出者中位PFS为5.1个月、中位OS为9.5个月,均显著劣于不可检出者的8.3个月和19.4个月,多因素分析仍保持关联。
要点
- 治疗期间可检出HOXA9甲基化ctDNA与更差的PFS和OS相关
- 治疗3周期后可检出者中位PFS 5.1个月 vs 8.3个月,中位OS 9.5个月 vs 19.4个月
- 基线可检出但后续转阴者临床结局最佳,其次为全程不可检出者
核心结论
- 纵向监测HOXA9甲基化ctDNA临床可行,且与铂耐药BRCA突变卵巢癌PARP抑制剂治疗后的PFS和OS强相关。
- HOXA9甲基化ctDNA有望作为预测性生物标志物,辅助该人群的临床决策。
研究设计与样本
- 研究为II期试验(测试veliparib)的伴随生物标志物分析,纳入32例铂耐药BRCA突变卵巢癌患者。
- 在基线和每个治疗周期前采用微滴数字PCR检测HOXA9启动子甲基化ctDNA。
主要发现
- 治疗中检出HOXA9甲基化ctDNA与更差临床结局相关,首周期后即显现并贯穿治疗全程。
- 治疗3周期后可检出者中位PFS为5.1个月,不可检出者为8.3个月。
- 治疗3周期后可检出者中位OS为9.5个月,不可检出者为19.4个月(P<0.0001和P=0.002)。
- 基线可检出但后续转阴者结局最佳,其次为全程不可检出者,关联在多因素分析中保持。
临床怎么用
- 可在PARP抑制剂治疗前及每周期前采血行HOXA9甲基化ctDNA检测,动态评估治疗反应与预后。
- 治疗早期(如3周期后)仍可检出者提示预后不良,可考虑加强监测与提前讨论治疗调整。
局限性
- 样本量小(n=32),来自单一日照veliparib的II期试验人群。
- 结论需在更大规模及其他PARP抑制剂人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a novel treatment option in BRCA-mutated ovarian cancer (OC); however, responses are variable and there is a lack of prognostic and predictive biomarkers. We therefore investigated whether homeobox A9 (HOXA9) promoter methylation in circulating tumour DNA (meth-ctDNA) can serve as a biomarker in patients with platinum-resistant BRCA-mutated OC, undergoing treatment with a PARP inhibitor. METHODS: Patients (n = 32) were enrolled as part of a phase II trial testing veliparib in platinum-resistant BRCA-mutated OC. HOXA9 meth-ctDNA was determined at baseline and just before each treatment cycle using digital droplet polymerase chain reaction. Methylation status and change in methylation compared with baseline were correlated with overall survival (OS) and progression-free survival (PFS). RESULTS: Detection of HOXA9 meth-ctDNA during treatment with a PARP inhibitor was associated with worse clinical outcomes. This association was apparent after the first cycle of treatment and maintained throughout treatment. After three treatment cycles, patients with detectable HOXA9 meth-ctDNA had a median PFS of 5.1 months compared with 8.3 months for patients without, and a median OS of 9.5 months compared with 19.4 months (p < 0.0001 and p = 0.002, respectively). Patients with detectable HOXA9 meth-ctDNA at baseline, but subsequent undetectable levels, had the most favourable clinical outcome, followed by patients with undetectable levels throughout. These associations were maintained in multivariate analysis. CONCLUSIONS: Longitudinal monitoring of HOXA9 meth-ctDNA is clinically feasible and is strongly correlated to clinical outcomes (PFS, OS), suggesting that it may serve as a valuable predictive biomarker to inform clinical decision-making in the setting of platinum-resistant BRCA-mutated OC treated with a PARP inhibitor.
引用
- Rusan M, Andersen RF, Jakobsen A, et al. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. Eur J Cancer. 2019. PMID: 31865042. doi:10.1016/j.ejca.2019.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。